SCHEDULE 13G/A: Capital Research Global Investors Amends Stake in Insulet Corp., Reports 8.7% Beneficial Ownership

Capital Research Global Investors has filed an Amendment No. 10 to its Schedule 13G, disclosing a beneficial ownership of 8.7% in Insulet Corp.'s common stock as of March 31, 2025.

Summary

• Capital Research Global Investors (CRGI) filed an Amendment No. 10 to Schedule 13G regarding its beneficial ownership in Insulet Corp.
• As of March 31, 2025, CRGI beneficially owns 6,076,540 shares of Insulet Corp. common stock.
• This represents 8.7% of the class, based on 70,226,104 shares believed to be outstanding.
• CRGI holds sole voting power over 6,071,196 shares and sole dispositive power over 6,076,540 shares.
• CRGI is an investment adviser and certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Insulet Corp.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by a large institutional investor in a publicly traded company within the medical device and diabetes management industry. It reflects an investment position rather than operational or strategic industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming Capital Research Global Investors' continued investment in Insulet Corp. without intent to influence control.

Key Dates

Keywords

Insulet Corp., Capital Research Global Investors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Medical Devices, Diabetes Management